Gilead Sciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $8.51B | $480.0M | $5.67B | $4.59B | $6.23B | $123.0M | $5.39B | $5.46B |
| Depreciation & Amortization | — | — | — | — | — | — | — | — |
| Depreciation | $370.0M | $381.0M | $354.0M | $323.0M | $329.0M | $288.0M | $255.0M | $226.0M |
| Amortization | $2.40B | $2.40B | $2.30B | $1.80B | $1.70B | $1.20B | — | — |
| Stock-Based Compensation | $894.0M | $835.0M | $766.0M | $637.0M | $635.0M | $643.0M | $636.0M | $845.0M |
| Net Cash from Operating Activities | $10.02B | $10.83B | $8.01B | $9.07B | $11.38B | $8.17B | $9.14B | $8.40B |
| Investing Activities | ||||||||
| Capital Expenditures | $563.0M | $523.0M | $585.0M | $728.0M | $579.0M | $650.0M | $825.0M | $924.0M |
| Business Acquisitions | $1.07B | $4.84B | $1.15B | $1.80B | $1.58B | $25.92B | $4.25B | $0 |
| Net Cash from Investing Activities | $-4.79B | $-3.45B | $-2.27B | $-2.47B | $-3.13B | $-14.62B | $-7.82B | $14.36B |
| Financing Activities | ||||||||
| Dividends Paid | $4.00B | $3.92B | $3.81B | $3.71B | $3.61B | $3.45B | $3.22B | $2.97B |
| Stock Repurchases | $1.92B | $1.15B | $1.00B | $1.40B | $546.0M | $1.58B | $1.75B | $2.90B |
| Net Cash from Financing Activities | $-7.75B | $-3.43B | $-5.13B | $-6.47B | $-8.88B | $770.0M | $-7.63B | $-12.32B |
| Net Change in Cash | $-2.43B | $3.91B | $673.0M | $74.0M | $-659.0M | $-5.63B | $-6.31B | $10.35B |
| Free Cash Flow | $9.46B | $10.31B | $7.42B | $8.34B | $10.81B | $7.52B | $8.32B | $7.48B |